CDER Eyes Prioritization, Timely Resolution Of Post-Marketing Safety Issues
Now that it has a system in place to track post-marketing drug safety issues, FDA’s Center for Drug Evaluation and Research is turning its attention to setting standard timeframes for investigating and addressing such signals.
You may also be interested in...
At workshop, agency acknowledges efficiency and implementation burdens that the myriad risk management program programs create, but developing a standardized approach will not easy task either.
Using 1998 authority would reduce the burden on sponsors, physicians and patients, industry group says.
FDA is searching for a way out of imposing a REMS when only a medication guide is required